Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 10;41(28):5537-5557.
doi: 10.1002/sim.9581. Epub 2022 Sep 17.

Progression models for repeated measures: Estimating novel treatment effects in progressive diseases

Affiliations

Progression models for repeated measures: Estimating novel treatment effects in progressive diseases

Lars Lau Raket. Stat Med. .

Abstract

Mixed models for repeated measures (MMRMs) are ubiquitous when analyzing outcomes of clinical trials. However, the linearity of the fixed-effect structure in these models largely restrict their use to estimating treatment effects that are defined as linear combinations of effects on the outcome scale. In some situations, alternative quantifications of treatment effects may be more appropriate. In progressive diseases, for example, one may want to estimate if a drug has cumulative effects resulting in increasing efficacy over time or whether it slows the time progression of disease. This article introduces a class of nonlinear mixed-effects models called progression models for repeated measures (PMRMs) that, based on a continuous-time extension of the categorical-time parametrization of MMRMs, enables estimation of novel types of treatment effects, including measures of slowing or delay of the time progression of disease. Compared to conventional estimates of treatment effects where the unit matches that of the outcome scale (eg, 2 points benefit on a cognitive scale), the time-based treatment effects can offer better interpretability and clinical meaningfulness (eg, 6 months delay in progression of cognitive decline). The PMRM class includes conventionally used MMRMs and related models for longitudinal data analysis, as well as variants of previously proposed disease progression models as special cases. The potential of the PMRM framework is illustrated using both simulated and historical data from clinical trials in Alzheimer's disease with different types of artificially simulated treatment effects. Compared to conventional models it is shown that PMRMs can offer substantially increased power to detect disease-modifying treatment effects where the benefit is increasing with treatment duration.

Keywords: Alzheimer's disease; disease progression model; disease-modifying treatment effects; mixed model for repeated measures; mixed-effects model.

PubMed Disclaimer

References

REFERENCES

    1. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med. 1997;16(20):2349-2380.
    1. Detry MA, Ma Y. Analyzing repeated measurements using mixed models. Jama-J Am Med Assoc. 2016;315(4):407-408. doi:10.1001/jama.2015.19394
    1. Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7:ARTN 28. doi:10.1186/s13195-015-0109-2
    1. Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):E322-E333. doi:10.1212/Wnl.0000000000007831
    1. Wang GQ, Berry S, Xiong CJ, et al. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018;37(21):3047-3055. doi:10.1002/sim.7811

LinkOut - more resources